Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients

NCT02297698 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

BIOLOGICAL: NeuVax vaccine
DRUG: Trastuzumab
DRUG: GM-CSF

Sponsor

Cancer Insight, LLC

Collaborators

[object Object]
[object Object]